NCT02056392 To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers Status COMPLETED Phase PHASE1
NCT02046850 To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers Status COMPLETED Phase PHASE1
NCT01998607 Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw Status COMPLETED Phase N/A
NCT01974349 To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Status COMPLETED Phase PHASE1
NCT01956669 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Status COMPLETED Phase PHASE2
NCT01948297 Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations Status TERMINATED Phase PHASE1
NCT01931761 Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers Status COMPLETED Phase PHASE1
NCT01929603 Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours Status COMPLETED Phase PHASE1
NCT01928940 Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) Status COMPLETED Phase PHASE2
NCT01921140 To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours Status COMPLETED Phase PHASE1
NCT01900028 To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours Status COMPLETED Phase PHASE1
NCT01894256 Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function Status COMPLETED Phase PHASE1
NCT01894243 Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment Status COMPLETED Phase PHASE1
NCT01851265 D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours Status COMPLETED Phase PHASE1
NCT01767454 Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma Status COMPLETED Phase PHASE1
NCT01626547 Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology Status COMPLETED Phase N/A
NCT01324258 Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors Status COMPLETED Phase PHASE1
NCT01266954 An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer Status COMPLETED Phase PHASE1
NCT01209091 Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden Status COMPLETED Phase N/A
NCT01184274 A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia Status COMPLETED Phase PHASE1